e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Environmental and occupational respiratory diseases: new exposure assessment methods, experimental exposure in animal and humans and mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Neutrophilic granule proteins in the occupational pulmonary diseases
G. Orlova, E. Surkova (Saint-Petersburg, Russian Federation)
Source:
Annual Congress 2013 –Environmental and occupational respiratory diseases: new exposure assessment methods, experimental exposure in animal and humans and mechanisms
Session:
Environmental and occupational respiratory diseases: new exposure assessment methods, experimental exposure in animal and humans and mechanisms
Session type:
Thematic Poster Session
Number:
4254
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Orlova, E. Surkova (Saint-Petersburg, Russian Federation). Neutrophilic granule proteins in the occupational pulmonary diseases. Eur Respir J 2013; 42: Suppl. 57, 4254
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Cytologicalfeaturesof bronchoalveolar lavage in different variants of exogenous allergic alveolitis
Source: International Congress 2014 – ILDs 5
Year: 2014
Bronchoalveolar lavage findings in patients with diffuse interstitial lung disease (DILDs)
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Significance of alveolar lavage in assessing the aggressivity of different occupational exposures
Source: International Congress 2015 – Occupational and environmental cohort investigations and population studies
Year: 2015
Bronchoalveolar lavage
Source: Eur Respir Mon; 2010: 48: 59–72
Year: 2010
Bronchoalveolar lavage tryptase levels are correlated with type 2 airway inflammation in mild asthma
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
Serum and bronchoalveolar exosomal miRNAs in pulmonary sarcoidosis
Source: International Congress 2015 – Sarcoidosis: pathogenesis
Year: 2015
Immune alveolitis profile in bronchoalveolar lavage of infiltrative lung diseases: not just counting matters.
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
The use of bronchoalveolar lavage (BAL) to assess lower airways inflammation in asthma
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016
Refractory severe asthma: Is presence of aspergillus in broncho-alveolar lavage significant?
Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues
Year: 2015
Eosinophilic lung disease
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Clinical, computed tomography, and cytological peculiarities of different variants of exogenic allergic alveolitis (EAA)
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
Hard metal lung disease – Role of bronchoalveolar lavage in the diagnosis
Source: International Congress 2014 – Occupational respiratory diseases: from drug-induced disease to COPD induced by the uranium industry
Year: 2014
Utility of bronchoalveolar lavage in vasculitis patients
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014
Can IL-4Ralpha and PAR-2 in bronchoalveolar lavage fluid serve as biomarker of fibroproliferative healing in interstitial lung diseases?
Source: International Congress 2015 – New insights into IIPs
Year: 2015
Clinical approach to pulmonary sarcoidosis
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016
The impact of smoking on bronchoalveolar lavage fluid (BALf) amyloid A concentration in patients with sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful?
Source: Eur Respir J 2011; 38: 761-769
Year: 2011
Bronchoalveolar lavage: how can we use it more effectively to define pathology?
Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases
Year: 2006
The impact of age on bronchoalveolar lavage (BAL) cytoimmunological pattern in interstitial lung diseases (ILD) and in healthy controls
Source: International Congress 2014 – ILDs 4
Year: 2014
Accelerated silicosis: A report of three patients
Source: International Congress 2015 – Occupational disease: clinical cases and series
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept